Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ImmunoGen Transitions To Commercial Stage With Elahere Launch

Executive Summary

The antibody-drug conjugate was approved by the US FDA for the treatment of FRα-positive, platinum-resistant epithelial ovarian cancer.

You may also be interested in...



Keeping Track: Early Thanks Given By ImmunoGen, Provention Bio; More PD-1/L1 Combo Approvals

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Ten Strategies For Success In Antibody-Drug Conjugate Development

The future looks rosy after a slow start for antibody-drug conjugates. But what are the best tactics to capture a slice of the growing opportunity?

IMMUNOGEN RAISES $ 5 MIL. IN VENTURE CAPITAL FUNDING FOR DEVELOPMENT

IMMUNOGEN RAISES $ 5 MIL. IN VENTURE CAPITAL FUNDING FOR DEVELOPMENT of its first product, Anti-B4-bR, an anticancer drug, the Cambridge, MA-based company announced in a May 5 press release. The company said that it "will use the proceeds to fund human clinical trials, beginning in the third quarter of 1988," and hopes "to become an independent and profitable therapeutics company by the early 1990's." Our objective is to maximize therapeutic impact while minimizing the side effects which occur when drugs react with normal, healthy cells," said ImmunoGen's president and CEO, Mitchel Sayare, who was VP for development at Xenogen until 1985. The primary ImmunoGen technology, the release explains, is the use of "immunoconjugates", which are powerful anticancer drugs, produced by "linking potent toxins, drugs or biologicals to cancer-seeking antibodies." The immunoconjugates act as target agents to specific disease sites in the body. The therapeutic use of these drugs would be to kill cancer cells while leaving normal cells unharmed. The company hopes to "replace conventional chemotherapeutics" and "reduce the incidence and severity of side effects" associated with chemotherapy with the new technology. ImmunoGen currently licenses four patents for acid-labile and photo-labile linkers (conjugates), developed under a licensing agreement with the Dana-Farber Cancer Institute. The agreement provides the company with "broad access to one of the most extensive monoclonal antibody libraries in the world." The company has seven patent applications for "proprietary toxins" and "directed immunotherapy methods." ImmunoGen's early product development, focusing on Acute Myelogenous Leukemia (AML), was conducted at the Dana-Farber Cancer Institute. Since then, ImmunoGen has built new facilities in Cambridge, Mass. and has entered into an agreement with E. Merck of West Germany, "for exclusive worldwide marketing rights to ImmunoGen's lung cancer product." Founded in 1981, to "develop and commercialize monoclonal-based therapeutics," ImmunoGen is a privately-held company whose investors include Harvard Management Co., Montgomery Medical Ventures, and TA Associates. In September 1987, ImmunoGen hired James Taylor, former chief regulatory officer at Carter-Wallace, to promote a working liaison with the Center of Biologies at the FDA.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147369

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel